FDA Designation of Prevor’s Chemical Skin Wash as ‘Drug’ was Arbitrary, Court Finds



DOCUMENTS
  • Opinion


WASHINGTON, D.C. — A federal judge has concluded that the Food and Drug Administration’s decision to designate a skin wash used to alleviate workplace chemical exposure as a drug, rather than a device, was arbitrary and needs to be reconsidered.

Judge Rosemary M. Collyer of the U.S. District Court for the District of Columbia did not order the agency to reclassify Prevor’s Diphoterine™ Skin Wash, which would allow different standards and costs for approvals, but concluded that the FDA failed to adequately explain its rationale.

Judge Collyer commented in her Sept. 25 opinion that the FDA’s post-decision issuance of …






UPCOMING CONFERENCES




HarrisMartin's MDL Conference

December 04, 2024 - New York, NY
Virgin Hotels NYC

MORE DETAILS



HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference

January 10, 2025 - Long Beach, CA
The Westin Long Beach

MORE DETAILS